Democritus University of Thrace (DUTH)
Λειτουργική διάκριση των ισομορφών TAp73 στην ογκογένεση
Abstract
dc:descriptionThe p73 gene encodes the tumor suppressive full-length TAp73 and N-terminal-truncated DNp73 isoforms that act as dominant negative inhibitors of TAp73. The overall effect of p73 in oncogenesis is thought to depend on the TAp73 to DNp73 isoforms’ ratio. TAp73 isoforms include a number of C-terminal variants (namely TAp73α, TAp73β, TAp73γ, TAp73δ, TAp73ε, TAp73ζ and TAp73η) as a result of alternative splicing in 3′-end. TAp73 isoforms differ in their transcriptional activities, as estimated by their transactivation efficiency on typical p53 targets, such as the p21Waf 1/Cip1, a key component of cell cycle regulation. Each TAp73 isoform not only activates the same targets to a different extend, but it also seems to have distinct gene targets. Data on the most studied TAp73α and TAp73β isoforms clearly highlight that, at least these isoforms, have opposing effects on the same target genes and they can also transactivate different targets. A number of recent studies highlight physical properties, as well as specific functional domains and residues of C-terminal tail of TAp73 isoforms that enhance or impair their transcriptional activity and apoptotic efficiency. These are: a) The C-terminal electrostatic charge, b) the Glu/Pro-rich and Pro-rich regions, c) the PPPPY motif d) the SAM domain and extreme C terminus (17). Oncogenesis includes well defined steps, through which “successful” genetic changes offer a growth advantage to normal cells, leading to their progressive transformation into cancer cells, in a process analogous to Darwinian evolution. In 2000, Hanahan et al. reported six steps (or hallmarks) in this process, i.e. sustaining proliferative signaling, evading growth suppressors, activating invasion and metastasis, enabling replicative immortality, inducing angiogenesis and resisting cell death. In 2011, Hanahan et al. (1) added two more hallmarks in this crucial list, i.e. reprogramming of energy metabolism and evading immune destruction, as well as two enabling characteristics, i.e. tumor-promoting inflammation and genome instability. Strikingly, TAp73 isoforms inhibit all these hallmarks and enabling characteristics, thus drastically influencing processes that underlie cancer promotion, progression and metastasis.The discovery of microRNAs (miRNAs) and their link with cancer has opened a new era in cancer therapeutics. Approximately, 19 - 25 nucleotides long, miRNAs can up-regulate or down-regulate gene expression in many cancer types and are respectively categorized as oncogenes (oncomirs) or tumor suppressors. Expression proles of miRNAs with biomarker potential can be used for the classication, diagnosis, therapeutic treatment, and prognosis of different cancer types. miRNA mimics and miRNA antagonists are the two main approaches to miRNA-based cancer therapies. The aim of this study is the functional distinction of the TAp73 isoforms in carcinogenesis. The TAp73α, TAp73β and TAp73γ isoforms were evaluated for their ability to induce specific miRNA signatures and to elucidate the underlying mechanisms of the inhibition of cell proliferation, cell migration and cell invasion. p53 family members, such as p53 and p63, antagonize epithelial to mesenchymal transition (EMT) processes through crucial microRNAs (miRNAs) that down-regulate EMT markers. However, to date, there are no published reports on p73-induced miRNAs that suppress EMT. In this study we examined which miRNAs are directly induced by the TAp73α, TAp73β and TAp73γ isoforms and inhibit the hallmarks and enabling characteristics of cancer.Using wound healing assays and Western blot, we showed that TAp73 isoforms differentially inhibit cell migration in vitro and alter levels of prometastatic EMT markers. To test whether this effect is also miRNA-mediated, we searched for miRNAs that are directly upregulated upon TAp73 induction, using high-throughput approaches (miRNA Micro Arrays). We found that TAp73 isoforms transactivate miRNAs with putative EMT-related targets, namely the well-studied TAp73 target miR-34a-5p and the still uncharacterized miR-3158-5p. miR-3158-5p was further identified as a direct TAp73 target, using ChIP and luciferase assays. It also down-regulates the EMT marker vimentin and inhibits cancer cell proliferation, migration and invasiveness in vitro. miR-3158-5p is under-expressed in breast cancer cell lines with high proliferation and invasive potential compared to breast cancer cell lines with low proliferation and invasive potential. MDA-MB-231 and MDA-MB-468 stably transfected clones expressing MIR3158 were constructed. These breast cancer cell lines are highly invasive. The inhibition of cell proliferation, colony formation, migration and invasion in these expressing MIR3158 clones was established by proliferation assay, colony formation assay, wound healing assay and invasion assay, respectively. In vivo zenografts were performed in SCID mice using MDA-MB-231 and MDA-MB-468 stably transfected clones and the anti-proliferative effect of MIR3158 was evaluated by measuring the volumes of the tumors that were formed during the experiment compared to the corresponding negative control mock clones. Furthermore, using bioinformatics tools we managed to identify and characterize the homologous mouse MIR3158 gene. This so called mmu-miR-3158Like gene was cloned into an expression vector and A5 skin cancer mouse cells we transiently transfected. We managed to identify two novel mouse mature miRNAs, namely mmu-miR-3158L-1 and mmu-miR-3158L-2. Finally, using bioinformatics tools we managed to predict that these mature mouse miRNAs directly target the mRNA of mouse vimentin and we showed that the expression levels of mouse vimentin were diminished upon the expression of the novel mouse MIR3158Like gene.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Galtsidis, Sotirios
- Γαλτσίδης, Σωτήριος
Subjects
dc:subject × 18Rights
dc:rights- Statement dc:rights
-
- BY_NC_ND
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/38842